NetworkNewsBreaks – Willow Biosciences Inc. (TSX
Post# of 23
(Total Views: 120)
Posted On: 04/20/2021 4:17:00 PM
NetworkNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Completion of Groundbreaking Study on CBG Use on Skin
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has completed a series of studies evaluating the safety and anti-inflammatory, anti-aging, and antimicrobial properties of its cannabigerol (“CBG”) when used on skin. The studies were conducted in collaboration with Signum Biosciences Inc., Willow’s development partner. The company announced that the studies show that Willow CBG is safe and effective when used on the skin and around the eye area; data indicates the ingredient can act as a more potent antioxidant and anti-inflammatory for certain skin applications than plant-derived cannabidiol (“CBD”). Willow will present the results of its findings at the upcoming Society for Investigative Dermatology (“SID”) meeting, scheduled for May 3–8, 2021; the company also noted it will make the full data available on its website on May 3. “Demonstrating the safety and benefit of a new ingredient like Willow’s CBG is a critical step in commercialization and it’s one that we take seriously at the Company,” said Willow Biosciences chief operating officer Dr. Chris Savile in the press release. “Willow’s CBG is now clinically tested to be safe for sensitive skin and demonstrated in the laboratory to act as a potent antioxidant, anti-inflammatory and anti-microbial. Most interestingly, Willow CBG was shown to be as potent or more potent than CBD, in some cases up to twice as potent, in the performed assays. We believe the clinical work on human skin and in vitro models with CBG are the first of their kind to be reported and we are very excited to share the results with our stakeholders and industry.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has completed a series of studies evaluating the safety and anti-inflammatory, anti-aging, and antimicrobial properties of its cannabigerol (“CBG”) when used on skin. The studies were conducted in collaboration with Signum Biosciences Inc., Willow’s development partner. The company announced that the studies show that Willow CBG is safe and effective when used on the skin and around the eye area; data indicates the ingredient can act as a more potent antioxidant and anti-inflammatory for certain skin applications than plant-derived cannabidiol (“CBD”). Willow will present the results of its findings at the upcoming Society for Investigative Dermatology (“SID”) meeting, scheduled for May 3–8, 2021; the company also noted it will make the full data available on its website on May 3. “Demonstrating the safety and benefit of a new ingredient like Willow’s CBG is a critical step in commercialization and it’s one that we take seriously at the Company,” said Willow Biosciences chief operating officer Dr. Chris Savile in the press release. “Willow’s CBG is now clinically tested to be safe for sensitive skin and demonstrated in the laboratory to act as a potent antioxidant, anti-inflammatory and anti-microbial. Most interestingly, Willow CBG was shown to be as potent or more potent than CBD, in some cases up to twice as potent, in the performed assays. We believe the clinical work on human skin and in vitro models with CBG are the first of their kind to be reported and we are very excited to share the results with our stakeholders and industry.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)